Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses

Key facts

Sponsor

Stanford University

Principal Investigator

Alexandra L Goodyear, MD, MS

Stanford University

Intervention

Alpha1-antitrypsin(drug)

Eligibility

18-75 years · All sexes

Timeline

2014

Study locations (1)

• Stanford University, Stanford, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT05909761
  Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
  Amgen
• RECRUITINGPHASE3NCT05199688
  A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
  Hoffmann-La Roche
• RECRUITINGPHASE4NCT07420296
  Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
  Tianjin Medical University General Hospital
• RECRUITINGNCT06885957
  Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
  Tongji Hospital
• RECRUITINGPHASE1NCT06620809
  The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
  Tongji Hospital
• RECRUITINGNANCT06865274
  Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• RECRUITINGNANCT06780709
  Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
  Icahn School of Medicine at Mount Sinai
• ACTIVE NOT RECRUITINGPHASE3NCT06724809
  Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
  Alexion Pharmaceuticals, Inc.

See all trials for Neuromyelitis Optica →